Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmacorp Rx Inc. ( (TSE:PCRX) ) just unveiled an announcement.
PharmaCorp Rx Inc. announced an upsized C$20 million bought deal public offering due to strong investor demand. The offering involves the sale of 47.7 million units, each consisting of one common share and a half warrant, with proceeds intended for future acquisitions and working capital. The closing is expected around November 12, 2025, pending regulatory approvals, and includes an over-allotment option for the underwriters to purchase additional units. This move is expected to bolster PharmaCorp’s strategic growth and enhance its market position in the Canadian pharmacy sector.
More about Pharmacorp Rx Inc.
PharmaCorp Rx Inc. is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. The company is building a national network of community pharmacies under the PharmaChoice Canada banner, currently operating seven such pharmacies, and plans to acquire more across Canada.
Average Trading Volume: 39,847
Technical Sentiment Signal: Sell
Current Market Cap: C$52.3M
See more data about PCRX stock on TipRanks’ Stock Analysis page.